The convergence of science and technology has ushered in a new era of innovation in the life sciences. Bayer is driving this paradigm shift by leveraging its leading expertise in biology, chemistry, data science, and artificial intelligence. The know-how of exceptional partners in strategic collaborations complements our internal expertise.
Bayer scientists draw on a diverse toolbox of modalities to deliver novel and differentiated medicines.
We have expanded our capabilities by adding platforms in chemoproteomics, cell therapies, and gene therapies. Cutting-edge technologies like generative artificial intelligence enable us to further increase R&D productivity.
By unlocking previously undruggable targets and applying breakthrough technologies, Bayer is challenging the limitations of medical treatment.
"The vast majority of our new development candidates have the potential to become the first or best product in their class."
By targeting diseases at the genetic and cellular level, cell and gene therapies offer an unprecedented opportunity to provide ground-breaking treatments that could prevent, halt or even reverse individual conditions. Bayer is committed to become a leader in this field developing an extensive portfolio of cell therapies and gene therapies to provide innovative treatment options for patients who urgently need them.
Precision drug development enables fast identification of the most promising targets. Bayer focuses on expanding the druggable target pool, developing efficacious and “kinder”, better tolerated medicines, as well as addressing drug resistance. In addition, we have built an early pipeline in tumor intrinsic pathways (also known as precision molecular oncology), next-generation immuno-oncology, and targeted alpha therapies (TATs).